Evidence map›Paper›PMID 25667844›Full record

ArticleEpilepsy & behavior case reports2013

Everolimus and intensive behavioral therapy in an adolescent with tuberous sclerosis complex and severe behavior.

Tanjala T Gipson, Heather Jennett, Lee Wachtel, Mary Gregory, Andrea Poretti, Michael V Johnston

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Epilepsy & behavior case reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Tanjala T GipsonTuberous Sclerosis Clinic, Kennedy Krieger Institute, Baltimore, MD, USA.
Heather JennettNeurobehavioral Unit, Kennedy Krieger Institute, Baltimore, MD, USA.
Lee WachtelNeurobehavioral Unit, Kennedy Krieger Institute, Baltimore, MD, USA.
Mary GregoryDepartment of Neurology and Developmental Medicine, Kennedy Krieger Institute, Baltimore, MD, USA.
Andrea PorettiSection of Pediatric Neuroradiology, Division of Pediatric Radiology, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Michael V JohnstonDepartment of Neurology and Developmental Medicine, Kennedy Krieger Institute, Baltimore, MD, USA.

Funding

NEUROLOGY SCIENCES ACADEMIC DEVELOPMENT AWARD (NSADA)K12NS001696 · NINDS · JOHNS HOPKINS UNIVERSITY · PI JOHNSTON, MICHAEL VAN DOREN · 1993 to 2016
$3.8M
NINDS NIH HHS K12 NS001696
6 · The paper itself

Abstract

backgroundSelf-injury and aggression have been reported in individuals with TSC (tuberous sclerosis complex), yet few data exist about treatment. Everolimus, an mTOR inhibitor, has been FDA-approved for subependymal giant cell astrocytomas (SEGAs) and renal angiomyolipomas in TSC. However, clinical use of everolimus with direct, real-time observations of self-injury and aggression in an individual with TSC has not been reported.

methodsDuring an inpatient admission to a neurobehavioral unit, real-time measurements of behaviors and seizures were recorded. An interdisciplinary team used these data to make treatment decisions and applied behavioral and pharmacological treatments, one at a time, in order to evaluate their effects.

resultsAggression and self-injury improved with applied behavioral analysis (ABA), lithium, and asenapine. Improvements in SEGA size, facial angiofibromas, seizures, and the most stable low rates of self-injury were observed during the interval of treatment with everolimus.

conclusionMechanism-based treatments in the setting of an evidence-based behavioral and psychopharmacological intervention program may be a model with utility for characterization and treatment of individuals with severe behavior and TSC.

Indexed as

ABA, applied behavioral analysisAggressionBehavioral intervention and epilepsyCYP3A4, cytochrome p450 3A4EverolimusFDA, Food and Drug AdministrationmTORC, mammalian target of rapamycin complexmTOR, mammalian target of rapamycinSEGA, subependymal giant cell astrocytomaSelf-injuryTSC, tuberous sclerosis complexTuberous sclerosis complex

Identifiers

PMID25667844
PMCPMC4150649

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.